We are live on ! Find out more

Thermo Fisher Scientific

TMO

Market cap $259B

698.34 USD

+15.69

2.3%

At close Updated Nov 3, 4:00 PM EST

Pre-market

After hours

710.00

+11.66

1.67%

1 day

2.3%

5 days

0.94%

1 month

3.19%

3 months

21.66%

6 months

50.96%

Year to date

17.86%

1 year

23.63%

5 years

8.71%

10 years

378.05%

About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

Employees: 125,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 51%

Neutral 47.1%

Negative 2%

Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses proprietary data and pattern recognition to highlight five stocks just under the surface that deserve attention.

Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet

Parnassus Value Equity Fund Q3 2026 Portfolio Review

Parnassus Value Equity Fund (Investor Shares) returned -1.38% (net of fees) for the quarter, underperforming the Russell 1000 Value Index's 2.61%. Top contributors include Thermo Fisher, CME Group, NICE, Willis Towers Watson and Verizon. Bottom contributors include Cummins, Applied Materials, Brookfield Renewable, Home Depot and AstraZeneca.

Parnassus Value Equity Fund Q3 2026 Portfolio Review

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore

Thermo Fisher Scientific Inc. delivered strong Q3 results, with 6% organic growth, EPS and sales beats, and raised full-year guidance. TMO's growth is driven by robust demand in clinical research, bioproduction, and electron microscopy, supported by recent strategic acquisitions. Operating margin reached 24.5%, aided by divestitures, acquisitions, and ongoing process improvements.

Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore

The Motley Fool

Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors

Thermo Fisher raised its 2026 organic revenue growth outlook to 4%. Third-quarter revenue reached $12.14 billion with 6% organic growth.

Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors

Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) posted upbeat third-quarter results and raised its FY2026 forecast.

Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings

Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript

Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript

Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript

Zacks Investment Research

TMO Q3 Earnings & Revenues Beat Estimates, Stock Down in Pre-Market

Thermo Fisher beats Q3 earnings and revenue estimates, with double-digit profit growth and wider margins, yet shares fall 4.1% in pre-market trading.

TMO Q3 Earnings & Revenues Beat Estimates, Stock Down in Pre-Market

Zacks Investment Research

Compared to Estimates, Thermo Fisher (TMO) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Thermo Fisher (TMO) Q3 Earnings: A Look at Key Metrics

Thermo Fisher Q3: The Recovery Is Real, And I'm Still Buying

Thermo Fisher Scientific Inc. delivered 6% organic growth, 120 bps margin expansion, and 39% free cash flow growth in Q3, validating the ongoing recovery. I maintain a Strong Buy rating on TMO, supported by accelerating earnings, improved profitability, and a declining net debt/EBITDA ratio (now 2.9x). Laboratory Products and Biopharma Services led with 10% organic growth, while Analytical Instruments posted 430 bps margin expansion, though Life Sciences and Diagnostics remain slower.

Thermo Fisher Q3: The Recovery Is Real, And I'm Still Buying

See News Rankings

Price charts implemented using Lightweight Charts™